3QAS

Structure of Undecaprenyl Diphosphate synthase

Summary for 3QAS

• Entry DOI: 10.2210/pdb3qas/pdb
• Descriptor: Undecaprenyl pyrophosphate synthase (2 entities in total)
• Functional Keywords: alpha-helix, isoprenoid biosynthesis, transferase
• Biological source: Escherichia coli
• Total number of polymer chains: 2
• Total formula weight: 56962.25

Authors

Cao, R.,Oldfield, E. (deposition date: 2011-01-11, release date: 2011-03-09, Last modification date: 2023-09-13)

Primary citation

Sinko, W.,de Oliveira, C.,Williams, S.,Van Wynsberghe, A.,Durrant, J.D.,Cao, R.,Oldfield, E.,McCammon, J.A.
Applying Molecular Dynamics Simulations to Identify Rarely Sampled Ligand-bound Conformational States of Undecaprenyl Pyrophosphate Synthase, an Antibacterial Target.
Chem.Biol.Drug Des., 77:412-420, 2011

PubMed Abstract: Undecaprenyl pyrophosphate synthase is a cis-prenyltransferase enzyme, which is required for cell wall biosynthesis in bacteria. Undecaprenyl pyrophosphate synthase is an attractive target for antimicrobial therapy. We performed long molecular dynamics simulations and docking studies on undecaprenyl pyrophosphate synthase to investigate its dynamic behavior and the influence of protein flexibility on the design of undecaprenyl pyrophosphate synthase inhibitors. We also describe the first X-ray crystallographic structure of Escherichia coli apo-undecaprenyl pyrophosphate synthase. The molecular dynamics simulations indicate that undecaprenyl pyrophosphate synthase is a highly flexible protein, with mobile binding pockets in the active site. By carrying out docking studies with experimentally validated undecaprenyl pyrophosphate synthase inhibitors using high- and low-populated conformational states extracted from the molecular dynamics simulations, we show that structurally dissimilar compounds can bind preferentially to different and rarely sampled conformational states. By performing structural analyses on the newly obtained apo-undecaprenyl pyrophosphate synthase and other crystal structures previously published, we show that the changes observed during the molecular dynamics simulation are very similar to those seen in the crystal structures obtained in the presence or absence of ligands. We believe that this is the first time that a rare 'expanded pocket' state, key to drug design and verified by crystallography, has been extracted from a molecular dynamics simulation.

PubMed: 21294851
DOI: 10.1111/j.1747-0285.2011.01101.x

Experimental method

X-RAY DIFFRACTION (1.7 Å)